The patient, with refractory folliculotropic MF, exhibited a rapid and significant response to the selective JAK1 inhibitor abrocitinib as an adjunct therapy alongside interferon and phototherapy with mild adverse events. The gene discussed is JAK1; the disease is mycosis fungoides.